The Effect of IL-7 (CYT107) on CD4 Counts in Patients With High Grade Gliomas and Severe Treatment-Related CD4 Lymphopenia After Concurrent Radiation and Temozolomide

Trial Profile

The Effect of IL-7 (CYT107) on CD4 Counts in Patients With High Grade Gliomas and Severe Treatment-Related CD4 Lymphopenia After Concurrent Radiation and Temozolomide

Suspended
Phase of Trial: Phase II

Latest Information Update: 01 Jun 2017

At a glance

  • Drugs Interleukin-7 (Primary)
  • Indications Lymphopenia
  • Focus Therapeutic Use
  • Most Recent Events

    • 25 May 2017 Planned End Date changed from 1 Aug 2018 to 1 Aug 2020.
    • 25 May 2017 Planned primary completion date changed from 1 Nov 2017 to 1 Nov 2019.
    • 25 May 2017 Status changed from recruiting to suspended.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top